Reata Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RETA  
78.85
-7.08 (-8.24%)
Products

Reata Pharmaceuticals Gets Fast Track Designation From The FDA For Omaveloxolone For The Treatment Of Friedreich'S Ataxia

Published: 11/19/2021 02:09 GMT
Reata Pharmaceuticals Inc - Ordinary Shares - Class A (RETA) - Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia.
Remain Committed to Submitting Our New Drug Application During Q1 of 2022.